Gilead opens trial over $20 billion drug
By Scott Graham, From The Recorder Gilead Sciences Inc. and Merck & Co. Inc. went to trial Monday in San Jose over the IP rights to Gilead’s $20 billion hepatitis C drug sofosbuvir. Lawyers for each company lauded the other’s…
Gilead can’t escape patent trial over hep c drugs
By Scott Graham, From The Recorder It looks as if Gilead Sciences will have to roll the dice on trial next month if it wants to protect the patent rights to its blockbuster hepatitis C treatment. It wouldn’t be the…